LN 145

Drug Profile

LN 145

Alternative Names: Autologous tumour infiltrating lymphocytes - Iovance Biotherapeutics; LN-145

Latest Information Update: 18 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator National Cancer Institute (USA); National Institutes of Health (USA)
  • Developer Iovance Biotherapeutics; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; T lymphocyte cell therapies
  • Mechanism of Action Immunomodulators; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cervical cancer
  • New Molecular Entity No

Highest Development Phases

  • Phase II Cervical cancer; Head and neck cancer; Non-small cell lung cancer; Osteosarcoma; Ovarian cancer; Soft tissue sarcoma

Most Recent Events

  • 01 May 2018 LN 145 receives Orphan Drug status for Cervical cancer in USA
  • 27 Apr 2018 Phase-II clinical trials in Ovarian cancer, Osteosarcoma and Soft tissue sarcoma (In adolescents, In adults, In the elderly) in USA (IV) (NCT03449108)
  • 28 Feb 2018 Phase-II clinical trials in Non-small cell lung cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (Parenteral) (NCT03419559)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top